Michael Seckler

GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada.

K2 Biotechnology Ventures LLC engages in accelerating the commercialization of university, medical center, and healthcare innovations. The private company is based in Chicago, IL. The company was founded by Kenneth B. Kashkin, Jane E. Kiernan.

FerGene, Inc. provides gene therapy solutions to urologists. The company is headquartered in Cambridge, MA.

Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ.